Bristol-Myers, Consumers Look To Centralize NJ Abilify Suits

By Rachel Graf (January 2, 2018, 1:58 PM EST) -- Bristol-Myers Squibb Co., Otsuka America Pharmaceutical Inc. and consumers of the companies' antipsychotic drug Abilify have urged a New Jersey state court to grant multi-county litigation status to at least 42 pending cases alleging that the treatment caused them to participate in compulsive activities such as gambling....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!